SALL4, a TF, through transcriptional mechanisms, is able to regulate signaling pathways or oncoproteins that advance tumor progression, such as Wnt/β-catenin20 and the apoptotic proteins Bcl-2 and Bax.21 A meta-analysis has linked the activation of SALL4 to an elevated risk of cancer-related mortality and recurrence, with SALL4-expressing patients experiencing a critical rise in overall death rates and disease relapse, underscoring that SALL4 is associated with reduced survival and serves as a potential biomarker for cancer prognosis.22 This evidence concerns the gene BCL2 and neoplasm.